论文部分内容阅读
目的探讨香砂六君丸在减轻大肠癌患者使用奥沙利铂+卡培他滨方案化疗过程中药物毒副反应和改善患者生活质量方面的作用。方法将符合研究标准60名大肠癌患者随机分为治疗组30例和对照组30例,均接受奥沙利铂+卡培他滨方案化疗两周期,治疗组首次化疗前一天开始服用口服香砂六君丸每次口服12粒,每日3次,直至2周期化疗结束。观察两组化疗期间胃肠道反应,骨髓抑制情况及治疗前后患者生活质量评分。结果治疗组Ⅲ-Ⅳ度恶心呕吐者6.7%,低于对照组的26.7%,治疗组无Ⅳ度恶心呕吐出现;治疗组Ⅲ-Ⅳ度腹泻者3.3%低于对照组的20.0%,治疗组无Ⅳ度腹泻出现。治疗组Karnofsky评分增加值≥10分者占30.0%,高于对照组的6.7%。两组之间差异均有统计学意义(P<0.05)。治疗组Ⅱ-Ⅲ度骨髓抑制者36.7%,对照组为40.0%,两组比较差异无统计学意义(P>0.05)。结论香砂六君丸对大肠癌患者采用奥沙利铂+卡培他滨方案化疗过程中减轻药物毒副反应和改善患者生活质量方面的作用显著。
Objective To investigate the role of Xiangsha Liujun Pills in alleviating drug toxicity and improving quality of life in patients undergoing chemotherapy with oxaliplatin + capecitabine in patients with colorectal cancer. Methods Sixty patients with colorectal cancer were randomly divided into treatment group (n = 30) and control group (n = 30). Both patients received oxaliplatin plus capecitabine regimen for two cycles. The patients in the treatment group started oral administration of sand Liujun pill orally each 12, 3 times a day until the end of 2 cycles of chemotherapy. The gastrointestinal reactions, bone marrow suppression and quality of life before and after treatment were observed in two groups. Results In the treatment group, the incidence of grade Ⅲ-Ⅳ nausea and vomiting was 6.7%, which was lower than that of the control group (26.7%). There was no grade Ⅳ nausea and vomiting in the treatment group. The incidence of grade Ⅲ-Ⅳ diarrhea in the treatment group was 3.3% lower than that in the control group No grade IV diarrhea. Treatment group Karnofsky score ≥ 10 points accounted for 30.0%, higher than the control group 6.7%. The differences between the two groups were statistically significant (P <0.05). The treatment group Ⅱ-Ⅲ degree of myelosuppression 36.7%, 40.0% in the control group, the difference between the two groups was not statistically significant (P> 0.05). Conclusion Xiangsha Liujun pill has a significant effect on alleviating drug toxicity and improving quality of life in patients with colorectal cancer through oxaliplatin + capecitabine regimen.